High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Nicotinamide, the principal form of niacin (vitamin B3), has been proposed to be neuroprotective in Parkinson's disease. However, the effects and mechanisms of nicotinamide on motor function in animals and on mitochondrial function in cellular systems have not been well studied. We hypothesized that niacin‐derived NAD(P)H as antioxidants and enzyme cofactors could inhibit oxidative damage and improve mitochondrial function and thus protect neurodegeneration and improve motor function. In the present study, the effects of nicotinamide on mitochondrial function and oxidative stress were studied in a 1‐methyl‐4‐phenylpyridinium (MPP+)–induced cellular model of Parkinson's disease, and the effects of improving motor dysfunction were studied in an α‐synuclein transgenic Drosophila Parkinson's model. Mitochondrial function was tested by measuring the activity of mitochondrial complex I and α‐ketoglutarate dehydrogenase, and oxidative damage was tested by measuring reactive oxygen species, DNA damage (8‐oxo‐7,8‐dihydro‐2′‐deoxyguanosine and Comet assay), and protein oxidation (protein carbonyls) levels. Nicotinamide at a relatively higher concentration, that is, 100‐fold of the level in the cell culture medium (101 mg/L), significantly protected SK‐N‐MC human neuroblastoma cells from an MPP+‐induced decrease in cell viability, complex I and α‐ketoglutarate dehydrogenase activity, and an increase in oxidant generation, DNA damage, and protein oxidation. In the Drosophila model, nicotinamide at 15 and 30 mg/100 g diet significantly improved climbing ability. These results suggest that nutritional supplementation of nicotinamide at high doses decreases oxidative stress and improves mitochondrial and motor function in cellular and/or Drosophila models and may be an effective strategy for preventing and ameliorating Parkinson's disease. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · cited 2×
“Nicotinamide is also an inhibitor of polyADPribose polymerase and the sir2 enzymes, NAD(1)dependent protein deacetylases that play key roles in transcriptional regulation, DNA repair, and life span regulation (Anderson et al., 1999; Bitterman et al., 2002).”
BackgroundEffects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 2×
“CoQ has been shown to attenuate 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in mice (Ebadi et al., 2001) and to slow the progressive deterioration of function in PD patients (Ebadi et al., 2001; Shults et al., 2002).”
BackgroundShults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity
Schulz, J. B., Ross Henshaw, D., Matthews, R. T., & Flint Beal, M. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90033-0 · Cited by 103 · cited 1×
“Nicotinamide alone or in combination with CoQ protects MPTP neurotoxicity in mice (Schulz et al., 1995; Anderson et al., 2006).”
BackgroundBirkmayer, J. G. D., Vrecko, C., Volc, D., & Birkmayer, W. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00018.x · Cited by 94
Cited by
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00313-x · Cited by 1,617
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
The pharmacological regulation of cellular mitophagy
Georgakopoulos, N. D., Wells, G., & Campanella, M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2287 · Cited by 319
Metadata
- Authors
- Jia, H., Li, X., Gao, H., Feng, Z., Li, X., Zhao, L., Jia, X., Zhang, H., & Liu, J.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 86
- Issue
- 9
- Pages
- 2083-2090
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2104457046
- Cited by
- 94
- References
- 6
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.